Tumor News and Research

RSS

Genomic study of non-Hispanic Black veterans with prostate cancer yields key insights for precision medicine

In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles and the Veterans Affairs (VA) National Precision Oncology Program found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care.

16 May 2025

Immune checkpoint inhibitors linked to increased myocarditis risk in lung cancer patients

A new editorial was published in Volume 12 of Oncoscience on May 2, 2025, titled "Immune checkpoint inhibitors and myocarditis: Lessons from a nationwide cohort study."

16 May 2025

Clinical trial against breast cancer explores the potential anti-tumor role of denosumab

Science and society collaboration is essential for scientific progress, especially in the health and biomedical fields where basic researchers, clinicians and patients are involved, as shown by the initial results of D-BIOMARK.

16 May 2025

Experts warn against unsupervised vitamin use and dietary trends in oncology

A new study coordinated by Dr. Salvatore Cortellino and Professor Antonio Giordano, President of the Sbarro Health Research Organization (SHRO) and molecular oncologist at Temple University and the University of Siena, offers a critical assessment of vitamin supplementation and popular dietary trends in the context of cancer prevention and treatment.

16 May 2025

Liquid biopsy advances precision medicine in gynecological cancers

A landmark review, now published in the Journal of Experimental & Clinical Cancer Research, offers a sweeping and authoritative synthesis on the use of liquid biopsy in gynecological oncology placing this emerging tool at the forefront of precision medicine for women.

16 May 2025

Targeting PME-1 may offer new strategies for treating neurological disorders and cancer

PME-1 is a protein that modifies other proteins by removing methyl groups, but high levels of PME-1 are observed in some diseases, including Alzheimer's disease (AD) and cancer.

16 May 2025

Harnessing nanomaterials to induce ferroptosis in cancer treatment

Announcing a new publication for Acta Materia Medica journal. Tumor ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a promising therapeutic strategy for combating cancers, particularly in cases involving cancer stem cells (CSCs) and drug resistance.

15 May 2025

Novel nanoparticle could make ultrasound-based cancer treatments more effective and safer

Researchers have created a new kind of nanoparticle that could make ultrasound-based cancer treatments more effective and safer, while also helping prevent tumors from coming back.

14 May 2025

Multiple laboratory techniques can provide a wealth of knowledge about brain cancer

Clinicians from the Johns Hopkins Kimmel Cancer Center and four other institutions have demonstrated that doctors can gain a wealth of knowledge about a patient's cancer by using multiple laboratory techniques to study tumor tissue taken from needle biopsies of glioblastoma, a highly aggressive form of brain cancer.

14 May 2025

Lipid overload in ascites weakens immune response in ovarian cancer

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

13 May 2025

DiffInvex identifies key genes driving chemotherapy resistance

Just as species adapt over generations, our body's cells accumulate DNA changes throughout life. Most are harmless, yet a few "driver" mutations give a cell a competitive edge and can spark cancer.

13 May 2025

AI tool enhances detection of tiny breast cancer signs in mammograms

Each year, millions of women undergo mammography to screen for breast cancer, yet tiny calcium specks—known as microcalcifications—often evade detection or are misread, leading to delayed diagnoses or unnecessary biopsies.

13 May 2025

Pentoxifylline offers no survival benefit for severe alcohol-associated hepatitis

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney injury (AKI), a complication that substantially worsens prognosis.

13 May 2025

‘Cell line atlas’ can help better understand biliary tract cancer biology

Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. BTC is a rare and aggressive group of cancers, carrying one of the worst prognoses in all of oncology.

12 May 2025

Exploring the role of RNA binding proteins and circular RNAs in cancer

The interaction between RNA-binding proteins (RBPs) and circular RNAs (circRNAs) has emerged as a key area of interest in understanding cancer biology.

12 May 2025

Review spotlights MYC as a multidimensional therapeutic target in cancer

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional therapeutic target.

12 May 2025

RANBP2 identified as key regulator in the progression of multiple solid tumors

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

12 May 2025

HER3 reemerges as a key driver of cancer progression and therapy resistance

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy.

12 May 2025

Blood-based biomarkers predict therapy failure in prostate cancer patients

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

12 May 2025

Blocking LSD1 restores immune response in early oral cancer

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving patient outcomes. However, the mechanisms driving the transition from preneoplastic lesions to full-blown cancer are not well understood.

11 May 2025